Anastasia V. Ustyugova
TA CardioMetabolism Respiratory, Binger Str 173
Ingelheim Am Rhein, RP 55216, Germany
Ingelheim Am Rhein, RP 55216, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial.
Journal: Clinical drug investigation
Published: October 01, 2024
Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: August 05, 2022
Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
Journal: Diabetes, obesity & metabolism
Published: July 13, 2022
Healthcare resource utilization in patients treated with empagliflozin in East Asia.
Journal: Journal of diabetes investigation
Published: August 10, 2021
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Journal: Journal of the American Heart Association
Published: May 25, 2021
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
Journal: Cost effectiveness and resource allocation : C/E
Published: March 04, 2021
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
Journal: Journal of comparative effectiveness research
Published: February 12, 2021
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: November 05, 2020
Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
Journal: Journal of comparative effectiveness research
Published: June 24, 2020
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Journal: European heart journal
Published: June 09, 2020
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: June 05, 2020
Last Updated: 09/26/2026